3D MRI for Quantitative Brain Imaging Gets FDA Nod
SyMRI 3D reportedly combines precise estimates of regional brain volume with improved resolution bolstering accuracy with lesion analysis.
The Food and Drug Administration (FDA) has granted 510(k) clearance for SyMRI 3D, a modality that may offer enhanced resolution and accuracy for brain magnetic resonance imaging (MRI) scans.
Combining quantitative MRI technology with isotropic resolution, SyMRI 3D provides improved accuracy in brain lesion analysis and facilitates brain structure and function assessments through precise brain region volume estimates, according to SyntheticMR U.S., the developer of the SyMRI 3D modality.
The newly FDA-cleared SyMRI 3D reportedly provides improved resolution that enhances accuracy of brain lesion analysis and better precision of brain region volume estimates, according to SyntheticMR U.S., the developer of the modality. (Image courtesy of SyntheticMR U.S.)
“Receiving 510(k) clearance for SyMRI 3D allows us to empower physicians to make more precise and informed decisions in diagnosis and treatment planning through quantitative imaging," said Jared Dixon, the president of SyntheticMR U.S.
SyMRI 3D will also be available to Philips customers as per a recently expanded partnership agreement between the two companies that was announced in November 2023.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
Study: AI-Generated ADC Maps from MRI More Than Double Specificity in Prostate Cancer Detection
June 5th 2025Emerging research showed that AI-generated ADC mapping from MRI led to significant increases in accuracy, PPV and specificity in comparison to conventional ADC mapping while achieving a 93 percent sensitivity for PCa.
